Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet. 2021 Jul 10;398(10295):131-142. doi: 10.1016/S0140-6736(21)00580-8.
Lancet. 2021.
PMID: 34246347
Clinical Trial.
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK.
Thuss-Patience PC, et al. Among authors: harle yge ml.
Lancet Oncol. 2017 May;18(5):640-653. doi: 10.1016/S1470-2045(17)30111-0. Epub 2017 Mar 23.
Lancet Oncol. 2017.
PMID: 28343975
Clinical Trial.
Item in Clipboard
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL.
Shah MA, et al. Among authors: harle yge ml.
Gastric Cancer. 2019 Jul;22(4):803-816. doi: 10.1007/s10120-018-00923-7. Epub 2019 Jan 31.
Gastric Cancer. 2019.
PMID: 30706247
Clinical Trial.
Item in Clipboard
A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
Li C, Agarwal P, Gibiansky E, Jin JY, Dent S, Gonçalves A, Nijem I, Strasak A, Harle-Yge ML, Chernyukhin N, LoRusso P, Girish S.
Li C, et al. Among authors: harle yge ml.
Clin Pharmacokinet. 2017 Sep;56(9):1069-1080. doi: 10.1007/s40262-016-0496-y.
Clin Pharmacokinet. 2017.
PMID: 27995530
Clinical Trial.
Item in Clipboard
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
Chen SC, Kagedal M, Gao Y, Wang B, Harle-Yge ML, Girish S, Jin J, Li C.
Chen SC, et al. Among authors: harle yge ml.
Cancer Chemother Pharmacol. 2017 Dec;80(6):1147-1159. doi: 10.1007/s00280-017-3443-1. Epub 2017 Oct 17.
Cancer Chemother Pharmacol. 2017.
PMID: 29043411
Clinical Trial.
Item in Clipboard
Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
Chen SC, Kagedal M, Gao Y, Wang B, Harle-Yge ML, Girish S, Jin J, Li C.
Chen SC, et al. Among authors: harle yge ml.
Cancer Chemother Pharmacol. 2018 Feb;81(2):421-422. doi: 10.1007/s00280-017-3488-1.
Cancer Chemother Pharmacol. 2018.
PMID: 29189914
Item in Clipboard
Cite
Cite